Skip to main content
. 2021 Oct;10(10):3787–3799. doi: 10.21037/tau-21-779

Table 5. Economic evaluation results.

PSA screening No screening Difference
Screening costs ¥297,354 ¥0 ¥297,354
End-of life costs ¥429,612 ¥448,669 −¥19,057
PC-related treatment costs ¥1,201,330 ¥874,751 ¥326,579
Total costs ¥1,928,296 ¥1,323,420 ¥604,876
Total LY 2,472.39 2,446.09 26.30
Total QALY 2,452.08 2,436.39 15.69
ICER ¥38,550/QALY

PSA, prostate specific antigen; PC, prostate cancer; LY, life year; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.